Ruiz-Ruigómez María, Fernández-Ruiz Mario, Pérez-Ayala Ana, Aguado José María
Unit of Infectious Diseases, Instituto de Investigación Hospital "12 de Octubre" (imas12), Hospital Universitario "12 de Octubre", CIBERINFEC, ISCIII, 28041 Madrid, Spain.
Department of Medicine, Universidad Complutense, Av. Séneca, 2, 28040 Madrid, Spain.
J Fungi (Basel). 2022 Aug 11;8(8):840. doi: 10.3390/jof8080840.
COVID-19-associated pulmonary aspergillosis (CAPA) have been documented during the COVID-19 pandemic. The vast majority of these patients do not meet the classic EORTC/MSGERC criteria for invasive pulmonary aspergillosis. The question arises as to whether there may have been an over-diagnosis of this disease. Here we review our experience and analyze the evolution of 27 patients who were diagnosed with CAPA during hospital admission. Surviving patients were followed-up for a mean time of 15 months (SD 3.78) by a group of experts and clinical records of diseased patients were reviewed. After expert evaluation and follow-up, 10 patients were finally assumed as CAPA according to expert opinion. These cases represent 40% of the initially CAPA assumed cases. Our data suggest the need to reconsider actual diagnosis criteria for CAPA what could drive to better identification of these patients.
在新冠疫情期间,已记录到新冠病毒相关肺曲霉病(CAPA)。这些患者中的绝大多数不符合侵袭性肺曲霉病的经典欧洲癌症研究与治疗组织/欧洲医学真菌学联合会(EORTC/MSGERC)标准。由此产生了一个问题,即这种疾病是否可能存在过度诊断的情况。在此,我们回顾我们的经验,并分析27例在住院期间被诊断为CAPA的患者的病情演变。存活患者由一组专家进行了平均15个月(标准差3.78)的随访,并对患病患者的临床记录进行了回顾。经过专家评估和随访,根据专家意见,最终认定10例患者为CAPA。这些病例占最初认定为CAPA病例的40%。我们的数据表明,有必要重新考虑CAPA的实际诊断标准,这可能有助于更好地识别这些患者。